You are here

Industry News

Advamed Smart Brief

September 18, 2018
A planned initial public offering of 3.3 million shares has been priced by Ra Medical Systems at $14 to $16 per share in hope -More
September 18, 2018
A round of Series A financing has brought in $22.5 million for Boston-based Miach Orthopaedics, which makes bioengineered imp -More
September 18, 2018
Sensus Healthcare has announced the closure of its public offering of about 2.2 million shares of its common stock, generatin -More
September 18, 2018
Switzerland-based startup Luciole Medical has raised $5.5 million in proceeds from a round of Series A financing, which it wi -More
September 18, 2018
Vygon, a French manufacturer of single-use medical devices, has paid an undisclosed amount for a 20% stake in Canadian startu -More
September 18, 2018
Drew Davies, former executive vice president and chief financial officer at Extreme Networks, has been tapped to hold those r -More
September 18, 2018
Providing advanced medical care in a patient's home once required the help of trained professionals.  -More
September 18, 2018
A patient at Catharina Hospital in the Netherlands was the first to undergo implantation of the Gore Excluder conformable abd -More
September 18, 2018
MYnd Analytics' Psychiatric EEG Evaluation Registry, a next-generation clinical phenotype database for predicting a patient's -More
September 18, 2018
AdvaMed lauded the FDA's proposed list of ways combination products can meet good manufacturing practice standards, although  -More

Industry News

PR Newswire
SAN DIEGO, CA ., Aug. 23, 2018 - Dthera™ Sciences, the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company's development-stage product, DTHR-ALZ.
Stat News
If your health care is covered by Medicare, like more than 55 million of your fellow Americans, where you live partly determines what Medicare will pay for. The process for deciding what items and services are covered from region to region needs reform.
PR Newswire
SAN ANTONIO, TX., May 23, 2018 - CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA post-market study of the company's COBRA PzF™ NanoCoated Coronary Stent (NCS) System. The clinical trial results demonstrated 4.3% target lesion revascularization, 0.3% late stent thrombosis and 8.6% major adverse...
Helius Medical Technologies, Inc.
NEWTOWN, PA.,  April 11, 2018 - Helius Medical Technologies, Inc. (“Helius” or the “Company”) today announced the pricing of an underwritten public offering of 2,141,900 shares of its Class A common stock and warrants to purchase 2,141,900 shares of its Class A common stock at a public offering price of US$7.47 per share and accompanying warrant, before underwriting discounts and commissions.  The net proceeds to the Company from this offering, after deducting the underwriting discounts,...
PR Newswire
California-based Myoscience, Inc. announced today that it received 510k clearance from the US FDA for Smart Tip with Nerve Stim, the latest innovative tip for Myoscience’s iovera° platform technology. With the FDA clearance for Smart Tip with Nerve Stim, physicians will be able to stimulate a nerve in advance of delivering iovera° cold therapy to the treatment area, reducing patient treatment times. Additionally, the use of Smart Tip with Nerve Stim enables physicians using iovera° to access...